3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
115
Cholangiocarcinoma
24
Carcinoma, Renal Cell
20
Liver Neoplasms
12
Stomach Neoplasms
10
Biliary Tract Neoplasms
10
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Breast Neoplasms
8
Neoplasms
7
Recurrence
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
5
Melanoma
5
Uterine Cervical Neoplasms
4
Thyroid Carcinoma, Anaplastic
4
Thyroid Cancer, Papillary
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Liver Diseases
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Carcinoma, Adenoid Cystic
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Adenocarcinoma
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Interventions
Carboplatin
177
Radiotherapy
139
Cisplatin
110
Pemetrexed
102
Docetaxel
93
Paclitaxel
92
Gemcitabine
78
Erlotinib Hydrochloride
73
Magnetic Resonance Spectroscopy
72
Radiosurgery
67
Bevacizumab
65
pembrolizumab
64
Etoposide
60
Blood Specimen Collection
60
durvalumab
53
Specimen Handling
48
Nivolumab
48
Surveys and Questionnaires
47
Drug Therapy
41
Standard of Care
35
Radiation
33
osimertinib
32
atezolizumab
32
Surgical Procedures, Operative
30
Topotecan
29
Irinotecan
29
Gefitinib
29
Educational Status
29
Early Intervention, Educational
29
Biopsy
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Neoplasms
×
lenvatinib
×
Clear all
NCT05384015
2026-04-30
PEERS
Fundación GECP
Phase 2
Active not recruiting
46 enrolled